Evidence & regulatory context
- Mechanism
- Anti-PcrV chicken egg-yolk antibody (IgY) against Pseudomonas PcrV; passive-immunotherapy biologic.
- Target
- Not recorded
- Injury models
- Burn
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseBurnUnspecifiedBALB/cFemale
Model: Pseudomonas aeruginosa infected burn wound model and acute pneumonia model in mice
Anti-PcrV IgY induced greater protection than control IgY and phosphate-buffered saline in both the murine acute pneumonia and burn wound models, improved opsonophagocytic killing and inhibited bacterial invasion of host cells.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.